The Economic Times

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

Aurobindo Pharma shares rose sharply after its subsidiary Lannett Company launched the generic equivalent of Advair Diskus in the US. The inhalation product, available in two strengths, marks the first commercialised product from Aurobindos inhalation pipeline. The stock has gained 41.16% year-to-date in 2026.